

# UC Davis

## UC Davis Previously Published Works

### Title

Prevalence and correlates of cognitive impairment in kidney transplant recipients.

### Permalink

<https://escholarship.org/uc/item/77p1n720>

### Journal

BMC nephrology, 18(1)

### ISSN

1471-2369

### Authors

Gupta, Aditi

Mahnken, Jonathan D

Johnson, David K

et al.

### Publication Date

2017-05-01

### DOI

10.1186/s12882-017-0570-1

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

RESEARCH ARTICLE

Open Access



# Prevalence and correlates of cognitive impairment in kidney transplant recipients

Aditi Gupta<sup>1,8\*</sup>, Jonathan D. Mahnken<sup>2</sup>, David K. Johnson<sup>3</sup>, Tashra S. Thomas<sup>1</sup>, Dipti Subramaniam<sup>4</sup>, Tyler Polshak<sup>1</sup>, Imran Gani<sup>5</sup>, G. John Chen<sup>4</sup>, Jeffrey M. Burns<sup>6</sup> and Mark J. Sarnak<sup>7</sup>

## Abstract

**Background:** There is a high prevalence of cognitive impairment in dialysis patients. The prevalence of cognitive impairment after kidney transplantation is unknown.

**Methods:** *Study Design:* Cross-sectional study. *Setting and Participants:* Single center study of prevalent kidney transplant recipients from a transplant clinic in a large academic center. *Intervention:* Assessment of cognition using the Montreal Cognitive Assessment (MoCA). Demographic and clinical variables associated with cognitive impairment were also examined. *Outcomes and Measurements:* a) Prevalence of cognitive impairment defined by a MoCA score of <26. b) Multivariable linear and logistic regression to examine the association of demographic and clinical factors with cognitive impairment.

**Results:** Data from 226 patients were analyzed. Mean (SD) age was 54 (13.4) years, 73% were white, 60% were male, 37% had diabetes, 58% had an education level of college or above, and the mean (SD) time since kidney transplant was 3.4 (4.1) years. The prevalence of cognitive impairment was 58.0%. Multivariable linear regression demonstrated that older age, male gender and absence of diabetes were associated with lower MoCA scores ( $p < 0.01$  for all). Estimated glomerular filtration rate (eGFR) was not associated with level of cognition. The logistic regression analysis confirmed the association of older age with cognitive impairment.

**Conclusion:** Cognitive impairment is common in prevalent kidney transplant recipients, at a younger age compared to general population, and is associated with certain demographic variables, but not level of eGFR.

**Keywords:** Cognitive impairment, Kidney transplantation, MoCA

## Background

Cognitive impairment is prevalent in as many as 50 to 87% of dialysis patients [1, 2] and influences quality of life, employment rates, treatment adherence, hospital admissions, health care costs, morbidity and mortality [3–5]. Kidney transplant recipients, like patients on dialysis, have several risk factors for cognitive impairment such as comorbid illness, depression, and lower level of physical activity [6, 7]. Kidney transplantation offers quality of life and survival advantages over dialysis [8]. Cognitive impairment in kidney transplant recipients is

associated with increased mortality [9, 10]. Some studies suggest cognitive impairment, especially in domains of verbal learning, memory and executive functioning in kidney transplant recipients when compared to healthy controls [11]. However, the actual prevalence of cognitive impairment in transplant recipients is unknown.

The knowledge of the prevalence of cognitive impairment is an important first step for designing future studies to assess the clinical impact of cognitive impairment and develop management strategies. Some studies indicate that cognition improves with kidney transplantation [12–16]. These studies, however, do not assess the prevalence of cognitive impairment in kidney transplant recipients as they were designed specifically to evaluate the impact of transplantation on cognition. The aim of this study is to evaluate the prevalence of cognitive impairment in kidney transplant recipients by screening

\* Correspondence: agupta@kumc.edu

<sup>1</sup>Division of Nephrology, University of Kansas Medical Center, Kansas City, KS, USA

<sup>8</sup>Division of Nephrology and Hypertension, Department of Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, MO 66160, USA

Full list of author information is available at the end of the article



eligible kidney transplant recipients. In addition, we evaluated the factors associated with cognitive impairment.

## Methods

### Study population

Adult kidney transplant recipients followed at the University of Kansas Kidney Transplant Clinic were included if they were i) English speaking; ii) without a history of acute stroke, concussion or traumatic brain injury within 2 months of testing and iii) with no acute illness at the time of participation. Patients were excluded if they i) had hearing or visual impairment; ii) were unable to read, write, speak or understand English; iii) had uncontrolled psychosis or seizure disorder; iv) were currently using antipsychotics or anti-epileptics v) received dual organ transplantation or vi) had a known history of cognitive impairment or dementia. Cognition was assessed during the clinic visit for post-transplant care. Eligible patients who attended the transplant clinic between May 2015 and June 2016 were approached. To minimize the acute effect of high dose steroids, surgery, and possible post-operative complications, cognitive assessments were performed only after the patient was at least 1 month post-transplant. As part of a standardized protocol, all patients were maintained on a mycophenolic acid compound and a calcineurin inhibitor with or without prednisone.

### Outcome variable

Cognition was assessed with the Montreal Cognitive Assessment (MoCA), a brief cognitive screening instrument (Additional file 1) [17]. The MoCA is a validated, clinic-based tool that samples from various domains of cognition and is sensitive in detecting mild cognitive impairment in several diseases, including Alzheimer's disease and vascular dementia [18, 19]. We chose MoCA over the more commonly used mini-mental state exam (MMSE) for detecting cognitive impairment, as MoCA has more focus on executive function, a domain more commonly affected in kidney disease [20]. Moreover, MoCA has been successfully used in kidney disease, with a good correlation with detailed neuropsychological testing and better results than MMSE [21]. MoCA consists of a single page test with a maximum score of 30. The MoCA takes less than 10 min to complete and assesses seven domains of cognition: visuospatial/executive, naming, memory (delayed recall), attention, language, abstraction and orientation. The original English version 7.1 was used (<http://www.mocatest.org/paper-tests/moca-test-full/>). Based on published validation data on patients from a memory clinic, we defined cognitive impairment as MoCA score of less than 26 [17]. The MoCA was administered by medical assistants who underwent an hour of training that included detailed

review of the online instructions along with practice sessions on mock patients. These medical assistants performed the test on the transplant recipients in a private examination room during the patients routine clinic visit to the transplant center.

### Exposure variables

Demographic and clinical variables that can potentially influence cognition such as age, gender, ethnicity, level of education, body mass index (BMI), blood pressure, history of smoking, diabetes, coronary artery disease, atrial fibrillation, transient ischemic attack (TIA) or stroke, cause for ESRD, serum hemoglobin, estimated glomerular filtration rate (eGFR), time on dialysis prior to transplant, and time after transplant were included in the analysis. Body mass index (BMI) and blood pressure were collected by medical assistants immediately before administration of MoCA. Demographic information and medical history were obtained through review of the patient's electronic medical record. Diabetes was defined as current or past use of oral hypoglycemic agents or insulin. Coronary artery disease was defined as history of myocardial infarction, angina pectoris, angioplasty or coronary artery bypass surgery. Hypertension was defined by past or current use of antihypertensive agents. However, hypertension was not included in the final analysis as all patients were on one or more antihypertensive agent at some point in time. The eGFR calculated by the Modification of Diet in Renal Disease equation closest to the day of MOCA assessment (the same day in most cases) was collected.

The data collection was initiated as a quality improvement project and was approved by the Institutional Review Board. Data were collected on paper forms and managed in standard case report forms in REDCap (Research Electronic Data Capture) a web-based, electronic data capture tool hosted on a secure, password protected, HIPAA compliant server [22].

### Statistical analysis

We compared baseline covariate values between patients with and without cognitive impairment using the *t* test for continuous variables (or rank sum test when *t* test assumptions were violated as indicated by residual analysis) and the Pearson's chi square test for categorical variables (or Fisher's exact test when expected cell counts were insufficient for Pearson's chi square test). To ensure accuracy of data collection (MoCA scores as well as data collected from patients medical records), two authors reexamined all the data entered for 50 random patients. We calculated the mean and the standard deviation for continuous variables, and the frequencies and the proportions for categorical variables. We further analyzed the prevalence in patients categorized by

five-year age groups. With the MoCA score being a continuous variable, we performed a multivariable linear regression analysis to study the association of these variables with cognitive performance. In model 1 of the multivariable regression analysis, we included all variables of interest that can affect cognition (age, gender, race, level of education, history of diabetes, coronary artery disease, smoking, stroke, and atrial fibrillation, BMI, serum hemoglobin, estimated glomerular filtration rate, systolic and diastolic blood pressure, time of dialysis, time since kidney transplant, and end stage renal disease secondary to diabetes). We used the adjusted R-square to determine model 2, in which we included selected variables from model 1 on the basis of their predictive relevance. The adjusted R-square criterion assesses the improvement in the amount of variation described relative to the number of parameters in the model. Residual analyses were conducted to assess the normality and constant variance assumptions of the multivariable linear regression models. We also assessed the adjusted associations of the variables selected for Model 2 with cognitive impairment defined as a MoCA score < 26. All tests were two-tailed. For all analyses,  $P < 0.05$  was considered statistically significant. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, 2002–2012).

## Results

### Patient characteristics

A total of 297 patients were approached for the MoCA test. Out of these, 22 patients were excluded from the analysis due to known history of mental retardation (five), stroke causing known cognitive deficits (two), hearing impairment (three), visual impairment (five), or inability to speak fluent English (seven). Eight patients refused to complete the assessment and two started the assessment, but did not complete it. After excluding the above 32 patients, 265 kidney transplant recipients completed the MoCA. Of these, 226 (>85%) had complete data and were included in the analyses. Examination of data for 50 random patients (total of 1250 data points) by two authors revealed high accuracy of data with a total of seven errors. As shown in Table 1, the mean age of the participants was 54.0 (SD 13.4) years. Participants were predominantly white, male, and with an education level of college or above. About half of the study participants were obese defined by a BMI  $\geq 30$  (50.9%). The mean eGFR was  $52 \pm 21$  ml/min/1.73 m<sup>2</sup>. The average time on dialysis prior to transplant was 2.3 years (SD 2.1) and the average time since transplant was 3.4 years (SD 4.1). Only 3% of the participants had a history of TIA or stroke and 21% had a history of coronary artery disease.

### Cognitive assessment

Fifty eight percent reached criteria for cognitive impairment. Table 1 compares the patients with and without cognitive impairment. The mean age of patients with cognitive impairment was higher than patients without cognitive impairment ( $p \leq 0.01$ ), and a lower proportion of female patients had cognitive impairment ( $p = 0.02$ ). Race, level of education, BMI, systolic and diastolic blood pressure, eGFR, time since transplantation, time on dialysis prior to transplantation, and a history of smoking, coronary artery disease, atrial fibrillation, diabetes, or the cause of ESRD were not different among those with and without cognitive impairment.

In the bivariate analysis, higher MOCA scores were associated with lower age ( $p < 0.001$ ), female gender ( $p < 0.001$ ), lower serum hemoglobin levels ( $p = 0.015$ ), and higher level of education ( $p = 0.003$ ). There was no association of the MOCA score with race, BMI, blood pressure, eGFR, time since kidney transplantation, time on dialysis prior to transplantation, history of smoking, stroke, diabetes, coronary artery disease, atrial fibrillation, and ESRD secondary to diabetes. Multivariable linear regression demonstrated that higher MOCA score was associated with younger age, female gender, a higher level of education, and diabetic status (Table 2). Model 1 includes all variables of interest entered in the analysis. Model 2 includes variables selected on the basis of their predictive relevance based on the adjusted R-square (Additional file 2).

When considering the dichotomous outcome of cognitive impairment older age was associated with higher risk (Table 3). With the higher prevalence of cognitive impairment in older transplant recipients, we also analyzed the prevalence of cognitive impairment by five-year age groups (Fig. 1). These results demonstrate an increased prevalence of cognitive impairment with older age, but notably also a high prevalence of cognitive impairment even in individuals less than 50 years old.

### Discussion

We examined the prevalence and covariates of cognitive impairment in a cohort of kidney transplant recipients. A majority of the transplant recipients with mean age of 54 years had cognitive impairment with the overall prevalence being more than two times the prevalence in those 65 years or older in the general population [23, 24]. Lower MoCA scores were associated with older age, male gender, and a lower level of education. These data underscore that cognitive impairment is common in kidney transplant recipients and additional studies are needed so as to understand the pathophysiology and impact of cognitive impairment in these individuals.

Several studies have shown that cognitive impairment is common in dialysis patients [1, 2]. In this study we

**Table 1** Demographic and clinical characteristics of study participants

Patient characteristics	All N = 226	MoCA <26 N = 131	MoCA ≥26 N = 95	p-value
Age (years)	54 (13.4)	56.7 (13.5)	51.3 (12.8)	<0.01
Gender				0.02
Female	89 (39.4)	43 (32.8)	46 (48.4)	
Race				0.57
Caucasian	165 (73.0)	93 (71.0)	72 (75.8)	
African American	43 (19.0)	28 (21.4)	15 (15.8)	
Other race	18 (8.0)	10 (7.6)	8 (8.4)	
Education level				0.08
≥ College	130 (57.5)	69 (52.7)	61 (64.2)	
BMI				0.65
≥ 30 (kg/m <sup>2</sup> )	115 (50.9)	65 (50)	50 (52.6)	
Blood Pressure				
Systolic (mmHg)	139 (18)	140 (19)	137 (17)	0.29
Diastolic (mmHg)	73 (12)	72 (12)	74 (13)	0.09
Serum hemoglobin (g/dl)	12.5 (2)	12.7 (2.1)	12.1 (1.9)	0.03
eGFR (ml/min/1.73 m <sup>2</sup> )	52 (21)	53 (21)	51 (22)	0.38
Time since KT (years)	3.4 (4.1)	3.3 (3.6)	3.6 (4.8)	0.72 <sup>a</sup>
Time on dialysis (years)	2.3 (2.1)	2.3 (1.93)	2.2 (2.3)	0.16 <sup>a</sup>
H/o smoking	95 (42.0)	57 (43.5)	38 (40.0)	0.60
H/o TIA/stroke	7 (3.1)	4 (3.1)	3 (3.2)	>0.99 <sup>a</sup>
H/o diabetes	84 (37.2)	49 (37.4)	35 (36.8)	0.93
H/o CAD	42 (21.2)	26 (19.9)	16 (16.8)	0.57
H/o Atrial Fibrillation	25 (11.1)	16 (12.2)	9 (9.5)	0.52
ESRD secondary to diabetes	57 (25.2)	34 (26.0)	23 (24.2)	0.77

Continuous variables = Mean (Standard deviation), Categorical variables = N (%)

The p-values indicate the comparison between MoCA <26 and MoCA ≥26.

BMI body mass index, eGFR estimated glomerular filtration rate, KT kidney transplant, H/o history of, TIA transient ischemic attack, CAD coronary artery disease

<sup>a</sup>Nonparametric test

show a high prevalence of cognitive impairment in kidney transplant recipients. We noted a higher prevalence of cognitive impairment with higher age. This trend is similar to that seen in the general population but occurs at a much younger age in kidney transplant recipients. For example, compared to a prevalence of 16–20% in adults 65 years or older in the general population [23, 24], we noted that a majority of the transplant recipients had cognitive impairment even at age of 40 years or less.

Not much is known about cognition and brain changes after kidney transplantation. Although cognition improves after kidney transplantation [12–16], our data suggest that that cognitive impairment in dialysis patients may not be entirely reversible. Several potential mechanisms may explain the cognitive impairment observed in kidney transplant recipients. Despite improvement in kidney function after transplantation, prolonged exposure to comorbid medical conditions including metabolic and vascular changes that are associated with kidney disease may result

in non-reversible cerebrovascular disease that persists after successful transplantation. Alteration of the microbiome, immunomodulation, and neurotoxicity from medications such as calcineurin inhibitors or steroids may also contribute to cognitive impairment in transplant recipients.

We did not detect a relationship between cognition and eGFR. This is in contrast to pre-dialysis CKD where the severity of cognitive impairment is correlated with severity of renal dysfunction [4, 25]. This implies that the etiology of cognitive impairment in dialysis and kidney transplant recipients cannot be entirely attributed to a lower level of GFR but that other factors mentioned above contribute. Patients on dialysis are indeed exposed to metabolic and hemodynamic alterations that might contribute to cognitive impairment. Although there is an association with eGFR in pre-transplant CKD, cognitive impairment in this population may as well be due to several other factors such as vascular alterations, chronic inflammation and comorbid conditions such as diabetes and hypertension. It is

**Table 2** Association of demographic and clinical variables with the level of cognition

Model 1			
Exposure variable	B Coefficient	95% Confidence interval	p-value
Age (/10 years)	-0.659	-1.04 to -0.28	<0.001
Female	1.321	0.41 to 2.23	0.01
African American <sup>a</sup>	-1.189	-2.31 to -0.05	0.04
Other race <sup>a</sup>	-0.122	-1.71 to 1.47	0.88
College education or above	0.826	-0.04 to 1.70	0.06
H/o diabetes	1.594	0.35 to 2.83	0.01
H/o CAD	-0.158	-1.33 to 1.01	0.79
H/o smoking	-0.573	-1.44 to 0.30	0.20
H/o TIA/stroke	0.381	-2.07 to 2.83	0.76
H/o A.fib	0.787	-0.65 to 2.22	0.28
BMI ( $\geq 30$ kg/m <sup>2</sup> )	0.343	-0.52 to 1.20	0.43
Serum hemoglobin (per g/dl)	-0.137	-0.38 to 0.11	0.27
eGFR (per ml/min/1.73 m <sup>2</sup> )	-0.005	-0.03 to 0.02	0.62
SBP (per mm Hg)	-0.011	-0.04 to 0.02	0.44
DBP (per mm Hg)	0.042	0.001 to 0.08	0.05
Time on dialysis (per year)	-0.104	-0.31 to 0.11	0.33
Time since KT (per year)	0.005	-0.11 to 0.12	0.93
ESRD secondary to diabetes <sup>b</sup>	0.027	-1.33 to 1.38	0.97
Model 2			
Exposure Variable	B Coefficient	95% Confidence interval	p-value
Age (/10 years)	-0.669	-1.00 to -0.34	<0.001
Female	1.363	0.50 to 2.23	0.002
College education or above	0.922	0.09 to 1.76	0.03
H/o diabetes	1.455	0.56 to 2.35	0.002
H/o smoking	-0.491	-1.34 to 0.36	0.25
H/o A. fib	-0.759	-0.58 to 2.10	0.27
Serum hemoglobin (per g/dl)	-0.120	-0.33 to 0.09	0.27
DBP (per mm Hg)	0.026	-0.01 to 0.06	0.15
Time on dialysis (per year)	-0.000	-0.35 to 0.04	0.12

Model 1 includes all variables of interest entered in the multivariable analysis. All variables are adjusted for the other variables. Model 2 includes variables selected on the basis of their predictive relevance using adjusted R-square criterion

H/o history of, ESRD end stage renal disease, TIA transient ischemic attack, BMI body mass index, eGFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, KT kidney transplant

<sup>a</sup>reference group: Caucasian race. <sup>b</sup>reference group: other causes of ESRD

also likely that cognitive impairment in pre-dialysis CKD takes several years to develop while level of eGFR in the transplant recipient only reflects a short period of the individual's life-time exposure to cognitive risk.

Diabetes and hypertension have been associated with cognitive impairment and white matter hyperintensities in the brain [26, 27]. We did not note a relationship between the presence of diabetes and cognitive impairment. This may be due to selection bias in that the healthier diabetic patients receive kidney transplants.

Despite the similarity between the general population and the transplant recipients in age related cognitive decline, cognitive impairment in transplant recipients may be different from Alzheimer's disease, the most common cause of cognitive impairment in the general population. For example, unlike Alzheimer's disease [28], women performed better in the cognitive assessments than men. In addition, as alluded to above, the pathophysiology of cognitive impairment in kidney disease, and by extrapolation, in kidney transplantation

**Table 3** Determinants of cognitive impairment<sup>a</sup>

Exposure variable	Adjusted odds ratio	95% Confidence interval	p-value
Age (per 10 year increase)	1.33	1.06 to 1.69	0.02
Female	0.57	0.32 to 1.03	0.06
College education or above	0.73	0.41 to 1.30	0.28
H/o diabetes	0.75	0.40 to 1.39	0.37
H/o smoking	1.01	0.56 to 1.82	0.98
H/o A. fib	0.88	0.34 to 2.27	0.79
Serum hemoglobin (per g/dl)	1.11	0.96 to 1.28	0.59
DBP (per mm Hg)	0.98	0.96 to 1.01	0.21
Time on dialysis (per year)	1.04	0.91 to 1.19	0.59

<sup>a</sup>Association of clinical variables with a MOCA score < 26 using logistic regression


recipients, more likely mimics vascular dementia rather than Alzheimer’s disease [20].

Our findings are clinically relevant. Cognitive impairment may have profound effects on outcomes of kidney transplantation [9, 10]. The care of transplant patients is a complex combination of polypharmacy, medication and dietary adherence, as well multiple outpatient clinic visits and tests. Medical adherence is affected by impairment in cognition and lack of adherence is a major cause for rejection and graft loss [29, 30]. Although mild cognitive impairment may not interfere notably with activities of daily living or be clinically evident, identifying these patients is important as cognitive impairment is a precursor to dementia with 5 to 20% of patients progressing to clinical dementia annually [31].

This study has some limitations. The cross sectional design precludes conclusions regarding cause and effect and does not provide information on whether cognition is stable, improving or deteriorating. Furthermore, it does not allow comparison of current level of cognition with that pre-transplant, or the association of current level of eGFR with decline in cognition in follow up. Although the prevalence of cognitive impairment was high, this may in fact be an underestimate as we excluded patients with known history of dementia. Depression can affect cognitive performance but was not assessed in this study. We excluded patients who did not speak English, which may affect generalizability. The clinical data were obtained from chart review which has its inherent limitations. We ensured accuracy of data collection by random sampling of 20% of the data points by two authors with 0.5% errors. In addition we used a structured case report form to abstract data. In this study we used MOCA to assess cognition. Although appropriate for this initial study, a screening tool such as MoCA may lack the specificity that can be achieved with more rigorous testing with detailed neurophysiological tests. However, for clinical practice, a simple tool such as MOCA is more practical. Furthermore, it is validated for use in outpatient clinics and can readily be applied to clinical practice in transplant clinics.

**Conclusions**

The prevalence of cognitive impairment in kidney transplant recipients is high. In contrast to the general population even younger transplant recipients have a high prevalence of cognitive impairment. This information should be taken into consideration during patient



**Fig. 1** Boxplot of MoCA scores by age range

education and monitoring of medical adherence. Further research is needed to understand the pathophysiology and consequences of cognitive impairment in transplant recipients. Strategies to help kidney transplant recipients cope with cognitive deficits should be developed.

## Additional files

**Additional file 1:** Description of the Montreal Cognitive Assessment. (DOCX 12 kb)

**Additional file 2:** Construction of model 2 in Table 2. (DOCX 11 kb)

## Abbreviations

BMI: Body mass index; CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate; ESRD: End-stage renal disease; MoCA: Montreal Cognitive Assessment; TIA: Transient ischemic attack

## Acknowledgements

We acknowledge the support from the Medical Assistants at the Renal Transplant Clinic in administering the cognitive tests.

## Availability of data and materials

Data were collected on paper forms and managed in standard case report forms in REDCap (Research Electronic Data Capture) a web-based, electronic data capture tool hosted on a secure, password protected, HIPAA compliant server. The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

## Authors' contributions

AG: Participated in the study concept, analysis and interpretation of data, drafting the article, and revising it critically. JM: Participated in study design, analysis and interpretation of data and manuscript writing. DJ: participated in the study design, analysis and interpretation of data, and revising the manuscript critically. TT: Participated in data acquisition and interpretation, and critical review of the manuscript. DS: Participated in data analysis and preparation of the manuscript. TP: Participated data acquisition, data analysis and preparation of the manuscript. IG: Participated in study concept and design, data acquisition, and revision of the manuscript. GC: Participated in study concept and design, statistical methods and data analysis, and revision of the manuscript. JB: Participated in study design and concept, and critical revision of the manuscript. MS: Participated in study design and concept, statistical methods, and critical revision of the manuscript. All authors read and gave a final approval of the current version of the manuscript for this submission.

## Funding

This work was supported by an NIH Clinical and Translational Science Award grant (UL1 TR000001, formally UL1RR033179) awarded to the University of Kansas Medical Center, and internal support provided by KUMC Department of Medicine. This funding was used for statistical analysis and publication costs.

## Competing interests

The authors declare that they have no competing interests.

## Consent for publication

No individual person's data in any form (including individual details, images or videos) is used in this manuscript.

## Ethics approval and consent to participate

The data collection was initiated as a quality improvement project. The Human Subjects Committee, the designated Institutional Review Board (IRB) for the University of Kansas Medical Center evaluated the project and declared it IRB exempt as it did not constitute human subjects research even if presented or published. Per KU IRB policy, informed consent is not required for quality improvement projects.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Author details

<sup>1</sup>Division of Nephrology, University of Kansas Medical Center, Kansas City, KS, USA. <sup>2</sup>Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA. <sup>3</sup>Department of Psychology, Alzheimer's Disease Center University of Kansas, Lawrence, KS, USA. <sup>4</sup>Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA. <sup>5</sup>Division of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA. <sup>6</sup>Department of Neurology, Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, KS, USA. <sup>7</sup>Division of Nephrology, Tufts Medical Center, Boston, MA, USA. <sup>8</sup>Division of Nephrology and Hypertension, Department of Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA.

Received: 16 January 2017 Accepted: 2 May 2017

Published online: 12 May 2017

## References

- Kalirao P, Pederson S, Foley RN, et al. Cognitive impairment in peritoneal dialysis patients. *Am J Kidney Dis.* 2011;57(4):612–20.
- Murray AM, Tupper DE, Knopman DS, et al. Cognitive impairment in hemodialysis patients is common. *Neurology.* 2006;67(2):216–23.
- Bremer BA, Wert KM, Durica AL, Weaver A. Neuropsychological, physical, and psychosocial functioning of individuals with end-stage renal disease. *Ann Behav Med.* 1997;19(4):348–52.
- Kurella M, Chertow GM, Luan J, Yaffe K. Cognitive impairment in chronic kidney disease. *J Am Geriatr Soc.* 2004;52(11):1863–9.
- Drew DA, Weiner DE, Tighiouart H, et al. Cognitive function and all-cause mortality in maintenance hemodialysis patients. *Am J Kidney Dis.* 2015;65(2):303–11.
- van den Ham EC, Kooman JP, Schols AM, et al. Similarities in skeletal muscle strength and exercise capacity between renal transplant and hemodialysis patients. *Am J Transplant.* 2005;5(8):1957–65.
- Chilcot J, Spencer BW, Maple H, Mamode N. Depression and kidney transplantation. *Transplantation.* 2014;97(7):717–21.
- Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. *N Engl J Med.* 1999;341(23):1725–30.
- McAdams-DeMarco MA, Bae S, Chu N, et al. Dementia and Alzheimer's disease among older kidney transplant recipients. *JASN: Journal of the American Society of Nephrology;* 2016.
- Sharma A, Yabes J, Al Mawed S, et al. Impact of cognitive function change on mortality in renal transplant and end-stage renal disease patients. *Am J Nephrol.* 2016;44(6):462–72.
- Gelb S, Shapiro RJ, Hill A, Thornton WL. Cognitive outcome following kidney transplantation. *Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association.* 2008;23(3):1032–8.
- Radic J, Ljutic D, Radic M, Kovacic V, Dodig-Curkovic K, Sain M. Kidney transplantation improves cognitive and psychomotor functions in adult hemodialysis patients. *Am J Nephrol.* 2011;34(5):399–406.
- Griva K, Thompson D, Jayasena D, Davenport A, Harrison M, Newman SP. Cognitive functioning pre- to post-kidney transplantation—a prospective study. *Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association.* 2006;21(11):3275–82.
- Kramer L, Madl C, Stockenhuber F, et al. Beneficial effect of renal transplantation on cognitive brain function. *Kidney Int.* 1996;49(3):833–8.
- Teschner PE, Ginn HE, Bourne JR, Ward JW. Neurobehavioral responses to "middle molecule" dialysis and transplantation. *Transactions-American Society for Artificial Internal Organs.* 1976;22:190–4.
- Gupta A, Lepping RJ, Yu AS, et al. Cognitive function and white matter changes associated with renal transplantation. *Am J Nephrol.* 2016;43(1):50–7.
- Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc.* 2005;53(4):695–9.



18. Freitas S, Simoes MR, Alves L, Santana I. Montreal cognitive assessment: validation study for mild cognitive impairment and Alzheimer disease. *Alzheimer Dis Assoc Disord*. 2013;27(1):37–43.
19. Freitas S, Simoes MR, Alves L, Vicente M, Santana I. Montreal cognitive Assessment (MoCA): validation study for vascular dementia. *Journal of the International Neuropsychological Society: JINS*. 2012;18(6):1031–40.
20. Sarnak MJ, Tighiouart H, Scott TM, et al. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. *Neurology*. 2013;80(5):471–80.
21. Tiffin-Richards FE, Costa AS, Holschbach B, et al. The Montreal cognitive Assessment (MoCA) - a sensitive screening instrument for detecting cognitive impairment in chronic hemodialysis patients. *Plo S one*. 2014; 9(10):e106700.
22. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377–81.
23. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment. *J Intern Med*. 2004;256(3):240–6.
24. Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic study of aging. *Neurology*. 2010;75(10):889–97.
25. Davey A, Elias MF, Robbins MA, Seliger SL, Dore GA. Decline in renal functioning is associated with longitudinal decline in global cognitive functioning, abstract reasoning and verbal memory. *Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association*. 2013;28(7):1810–9.
26. Overman MJ, Pendleton N, O'Neill TW, et al. Glycemia but not the metabolic syndrome is associated with cognitive decline: findings from the European male ageing study. *The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry*. 2017;
27. Hawkins KA, Emadi N, Pearson GD, et al. Hyperinsulinemia and elevated systolic blood pressure independently predict white matter hyperintensities with associated cognitive decrement in the middle-aged offspring of dementia patients. *Metabolic brain disease* 2017; doi: 10.1007/s11011-017-9980-9.
28. Payami H, Zareparsy S, Montee KR, et al. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. *Am J Hum Genet*. 1996;58(4): 803–11.
29. Jindal RM, Joseph JT, Morris MC, Santella RN, Baines LS. Noncompliance after kidney transplantation: a systematic review. *Transplant Proc*. 2003;35(8): 2868–72.
30. Garcia MF, Bravin AM, Garcia PD, et al. Behavioral measures to reduce non-adherence in renal transplant recipients: a prospective randomized controlled trial. *Int Urol Nephrol*. 2015;47(11):1899–905.
31. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. *Ann Intern Med*. 2008;148(6):427–34.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

